Thus, it is intriguing to test in the future whether EA could be potentially a more effective anti-diabetic and anti-obesity agent than some of the currently prescribed monotherapeutic drugs such as DPP4 inhibitors, metformin, and GLP-1 analogs. This evidence concerns the gene GLP1R and obesity disorder.